PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Molecular cancer · 2023 · 1,738 citations · Matthew H Kulke
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
The New England journal of medicine · 2025 · 127 citations · Matthew H Kulke
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 270 citations · Matthew H Kulke
Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.
The New England journal of medicine · 2021 · 237 citations · Peter Westervelt
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 69 citations · Vatche Tchekmedyian
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 113 citations · Peter Westervelt
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 134 citations · Peter Westervelt
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 77 citations · Peter Westervelt